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Fibulin-2 is required for basement 
membrane integrity of mammary 
epithelium
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Fibulin-2 (FBLN2) is a secreted extracellular matrix glycoprotein which has been associated with tissue 
development and remodelling. In the mouse mammary gland, FBLN2 can be detected during ductal 
morphogenesis in cap cells and myoepithelial cells at puberty and early pregnancy, respectively. In an 
attempt to assign its function, we knocked down Fbln2 in the mouse mammary epithelial cell line EpH4. 
FBLN2 reduction led to an increase in the size of spheroidal structures when compared to scrambled 
control shRNA-transduced cells plated on Matrigel matrix. This phenotype was associated with a 
disruption of the collagen IV sheath around the epithelial spheroids and downregulation of integrin β1, 
suggesting a role for FBLN2 in stabilizing the basement membrane (BM). In contrast to mice, in normal 
adult human breast tissue, FBLN2 was detected in ductal stroma, and in the interlobular stroma, but 
was not detectable within the lobular regions. In tissue sections of 65 breast cancers FBLN2 staining 
was lost around malignant cells with retained staining in the neighbouring histologically normal tissue 
margins. These results are consistent with a role of FBLN2 in mammary epithelial BM stability, and that 
its down-regulation in breast cancer is associated with loss of the BM and early invasion.
Breast cancer is one of the most widespread types of cancer in females worldwide and one of the leading causes of 
cancer-associated deaths1,2. The tumour microenvironment (TME) is an important contributor to breast cancer 
formation and progression involving multiple cell types, as well as growth factors and modulators of the extra-
cellular matrix (ECM)3,4. ECM proteins themselves also play a central role in the TME. For instance, periostin 
(POSTN), fibronectin (FN), tenascin-c (TN-C), and hyaluronan are all well documented components of the met-
astatic niche in cancerous tissues such as breast cancer5,6. However, our understanding of the contribution that the 
individual ECM components make to disease development and progression is still limited.
Fibulin-2 (FBLN2) is a secreted extracellular glycoprotein originally identified in the embryonic endocardial 
cushion tissue and the heart valves of adult mice and humans7. FBLN2 has been associated with the development 
and remodelling of tissues, as it is expressed at sites of epithelial-mesenchymal transition during endocardium 
formation in the developing heart and during neural crest development8. It is also expressed by the smooth mus-
cle precursor cells of developing aortic arch vessels9.
In the mouse mammary gland, FBLN2 has been specifically detected in and around the cap cells of the termi-
nal end buds during puberty in regions where the basement membrane (BM) is formed along the newly develop-
ing mammary ductal epithelium, as well as in myoepithelial cells during early pregnancy when the ductal ECM is 
remodelled to enable lateral branching to occur10. This expression pattern indicates a possible role in morphogen-
esis of the newly formed ducts. As FBLN2 has been shown to bind and bridge other BM proteins, including FN, 
nidogens, versican, and hyaluronan11, and links these proteins to form stable ECM networks12, we hypothesised 
that FBLN2 may be important for the formation of a new stable BM during mammary gland morphogenesis. 
However, fbln2 KO mice have no major mammary phenotype10 as the loss of FBLN2 is compensated by a reloca-
tion of other fibulin proteins, in particular FBLN111, while knockout of FBLN1 itself is lethal due to loss of BM in 
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small blood vessels leading to haemorrhage13. Therefore, there is a need for in vitro assays to be able to assess the 
possible function of FBLN2 in mammary gland morphogenesis.
BM integrity is crucial for the suppression of tumour invasiveness, and BM breakup and loss is a major hallmark 
of cancer progression14. Little is known about FBLN2′s role in cancer, though a role in tumour suppression has been 
suggested by recent studies on nasopharyngeal carcinoma15, colorectal cancer16, and in breast cancer cells17.
In this study, we further investigated the function of FBLN2 in normal mammary epithelial cells by knocking 
down FBLN2 in the mouse mammary epithelial cell line EpH4, and assessed its expression in normal and cancerous 
human breast tissue. Here we show that reduced FBLN2 levels in normal mammary epithelial cells are associated with 
a significant reduction in integrin β1 (ITGβ1) and a discontinuous BM, and that FBLN2 expression is gradually lost 
in areas of tumour invasion. Our results are consistent with a role for FBLN2 in retaining BM integrity, and demon-
strate an association between loss of FBLN2 expression and loss of BM in the progressing malignant breast tissue.
Results
FBLN2 knockdown induces enlarged cell morphology. Despite FBLN2′s distinct and selective expres-
sion around newly growing mammary epithelium, fbln2 KO mice did not display any mammary phenotype10. To 
investigate a possible role for FBLN2 during mammary epithelial development, we stably transduced FBLN2-
expressing mammary epithelial EpH4 cells with lentiviral shRNA constructs against Fbln2 (or scr control) and 
selected for stable transduction and shRNA expression by puromycin treatment. The three constructs reduced 
FBLN2 protein expression by 30–80% in 2D culture, and with a corresponding reduction at RNA level (Fig. 1a,b). 
Figure 1. Confirmation of FBLN2 KD and the effect on cell size. (a) FBLN2 and β-actin expression in 
three separate EpH4 lines stably transduced with FBLN2 shRNAs (#1-3) or with scr control as measured by 
western blot. Percentages show the relative expression of FBLN2 in the stably transduced cells normalised 
to β-actin expression (from same gel) and as measured by ImageJ software. (b) Quantitative PCR analysis 
of Fbln2 RNA expression in the three stably transduced lines with FBLN2 shRNAs compared to scr ctrl; 
expression was quantified relative to β-actin. Error bars show standard deviation for technical replicates. (c) 
Immunofluorescent analysis of FBLN2 expression in the stable KD cell lines, showing the different levels of 
membrane-associated FBLN2 in the three KD cell lines. (d) Phase contrast microscopy of cells showing the 
differences in morphology upon plating on plastic. Bars represent 100 μm.
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Down-regulation of FBLN2 protein expression was further confirmed in the stably transfected clones by a strong 
reduction in membrane-associated FBLN2 in immunofluorescent analysis (Fig. 1c). Microscopic analysis of the 
cells at confluency showed that Fbln2 KD cells were consistently larger than scr shRNA control cells and had 
enlarged nuclei (Fig. 1d), though surprisingly this cell size enlargement was not readily detectable by flow cyto-
metric analysis (Supplementary Fig. 1).
FBLN2 knockdown leads to enlarged colony formation in 3D culture. FBLN2 is a secreted BM 
protein and any effect on cell behaviour may therefore become mostly apparent when cells are grown in a 3D 
environment, which allows the formation of a BM around spherical cell colonies. KD cells were therefore analysed 
in a 3D assay involving growth in Matrigel matrix. While scr shRNA control-transduced EpH4 cells formed small 
evenly shaped round spheroids, the size of the spheroids was consistently increased in the Fbln2 KD cells with the 
strongest suppression of FBLN2 compared to the scr shRNA control cells (Fig. 2).
EpH4 Fbln2 KD cells when co-cultured with fibroblast show stellate branch pattern. To investi-
gate whether KD of FBLN2 affected the epithelial cells’ ability to branch, we co-cultured FBLN2 KD and scr con-
trol EpH4 cells with primary mammary fibroblasts in a Matrigel matrix. Fibroblasts had previously been shown 
to induce mammary epithelial branching in 3D culture when co-cultured with mammary epithelial organoids18. 
While the increased spheroidal size was still evident in Fbln2 KD cells, co-culture with fibroblasts led to a strongly 
increased stellate branch pattern compared to control scr ctrl cells, with either individual cells or thin tubules 
extending from the spheroids into the surrounding matrix (Fig. 3).
FBLN2 knockdown affects basement membrane integrity. Fibulins can interact directly with 
integrins and contribute to BM integrity9–11, with FBLN2 KO mice showing a blistering phenotype of the epi-
dermis of newborn mice similar to that of ITGα3 KO mice19. Integrin expression was therefore investigated in 
Figure 2. Size increase of Matrigel-embedded EpH4 cells associated with FBLN2 KD. (a) Phase contrast 
microscopy of the stably transduced EpH4 cells grown in Matrigel matrix expressing scr vector, shRNA#1, 
shRNA#2, or shRNA#3, showing the size increase in spheroids upon Fbln2 KD. Pictures are representative of 
three independent experiments. Scale bars represent 500 µm (top) and 100 µm (bottom). (b) Quantification 
of small and large spheroidal structures of stably transduced EpH4 cells grown in Matrigel matrix. Bars are 
standard error for three biological replicates.
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EpH4 spheroids. Although ITGα3 expression was increased in total protein extracts from 2D-plated FBLN2 KD 
cells with the strongest reduction in FBLN2 protein, this increase was not measureable when spheroids of the 
Matrigel-grown cells were assessed by immunofluorescence, while the strong reduction in FBLN2 expression was 
still evident (Fig. 4a,b). In contrast, ITGβ1 expression was strongly reduced in the FBLN2 KD cells as shown by 
western blot and when Matrigel-embedded structures were examined by immunofluorescence (Fig. 4a,b).
To test whether BM integrity was also affected by the decrease in FBLN2, 3D colonies of KD and control cells 
were stained for the basal membrane protein COLIV, a key component of the lamina densa. While scr control 
cells showed an evenly formed COLIV layer around the spheroids, FBLN2 KD cells had a discontinuous and 
irregular COLIV layer (Fig. 5), which was independent of the colony size. This finding is consistent with a role for 
FBLN2 in the formation of a stable COLIV-layer and hence BM integrity.
FBLN2 expression in human breast cancer. The BM has been recognised as an important barrier that 
suppresses tumour invasion and hence metastasis formation14,20. The role of FBLN2 in breast cancer has so far not 
been well studied and recent reports are contradictory about its contribution to tumour development17,21,22. Our 
in vitro results supported a role for FBLN2 in BM integrity, and we therefore hypothesised that in breast cancer 
FBLN2 expression would be expected to be reduced in line with progression from normal to invasive tissue. We 
therefore assessed FBLN2 expression in formalin-fixed histological sections from 65 breast cancer patients with 
invasive breast cancer with adjacent ductal carcinoma in situ (DCIS) as well as morphologically normal breast 
tissue to establish its role in disease progression to invasive cancer (Table 1).
Figure 3. EpH4 Fbln2 KD cells when co-cultured with fibroblast show a stellate branch pattern. Phase contrast 
microscopy of the stably transduced EpH4 cells (scr and cells with lowest (18%) expression of FBLN2) grown on 
Matrigel matrix, alone and co-cultured with fibroblasts. Bars represent 500 μm (top) and 100 μm (bottom). (b) 
Quantification of small large spheroidal structures and satellite structures with or without fibroblasts in control 
(scr) and shRNA#3 cells. The numbers are representative of two biological replicates.
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Immunohistochemical examination of morphologically normal breast tissue showed strong staining for 
FBLN2 around normal ducts at the myoepithelial cell/BM interface, as shown by staining of the same tissues for 
smooth muscle actin (SMA) and vimentin (Vim), (Fig. 6 and Supplementary Fig. 2) as well as in the interlobular 
stroma, where the ECM is intact and the collagen I/III network is unimpaired/coherent as demonstrated by the 
intensity of fibrous collagen staining with picrosirus red23. In contrast, FBLN2 expression was decreased in the 
intralobular stroma where the collagen I/III network was much less coherent (Fig. 6a,b,e,f). In DCIS and invasive 
tumour regions FBLN2 expression was either undetectable or weak when compared to the expression around 
normal ducts (Table 1). This was particularly obvious at the interface between normal ducts and tumour tissue, 
where ductal expression of FBLN2 was lost in regions of DCIS/invasive carcinoma (Fig. 6c,d). Pearson’s test 
showed a negative significant correlation (P < 0.001) between the level of FBLN2 expression and tumour grade 
(Supplementary Table 2).
To verify that the absence of FBLN2 in invasive cancerous areas was not a technical artefact, we stained 10 can-
cer tissue sections for other known markers of invasive and metastatic spread. Glycosaminoglycans (GAGs) are 
known modulators of cell-ECM interaction associated with cancerous tissues24, and we therefore assessed GAGs 
presence in relation to FBLN2 expression by Alcian blue staining. Morphologically normal tissue sections showed 
little GAGs staining in areas where FBLN2 staining was strong (Fig. 6I,j). In contrast, significant levels of GAGs 
were detected in the stroma surrounding tumour tissue within all tested sections with the less intact network of 
fibrous collagen, and where FBLN2 expression was absent (Fig. 6g,k,h,l). At the same time, the BM-associated 
ECM proteins tenascin C (TN-C) and periostin (POSTN) expression, whose expression has been associated with 
metastatic spread25,26, were all strongly expressed in these regions (Supplementary Figs 3 and 4).
Figure 4. Fbln2 KD is coupled with a reduction in Integrin beta 1 expression but not Integrin alpha 3. (a) 
Immunofluorescent analysis of FBLN2, ITGβ1 and ITGα3 expression in the stable KD cell lines with the lowest 
(18%) FBLN2 expression. Bars represent 50 μm (b) Western blotting analysis of ITGα3 and ITGβ1 relative to 
actin in protein extracts from 2D-plated scr ctrl and Fbln2 KD cells. (Note: The ITGα3 was measured on the 
same membrane as FBLN2 in Fig. 1a after antibody stripping; ITGβ1 and actin are from the same blot, though 
from equally loaded neighbouring parts of the gel).
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FBLN2 localizes to collagen IV/BM in human mammary tissue. Our in vitro data on EpH4 cells 
suggested that FBLN2 was necessary for a stable BM. To investigate whether FBLN2 expression was also associ-
ated with an intact BM in the human breast, we assessed co-expression of FBLN2 and COLIV in 10 out of the 65 
human breast cancer tissues and histologically normal tissue margins, which were randomly chosen. Consistent 
with a role for FBLN2 in BM stability, both proteins co-localised at and near the BM of morphologically normal 
Figure 5. Fbln2 KD affects the integrity of COLIV sheath in Matrigel-embedded EpH4 cells. 
Immunofluorescent analysis of COLIV expression through three confocal optical z-sections in the stable KD 
cell lines with the lowest FBLN2 expression, plated in Matrigel matrix. Bars represent 50 μm.
Intensity Score 0 1 2 3 N/A Total
morph. normal 
ducts 2 0 20 40 3 65
DCIS 42 14 0 0 9 65
invasive 45 16 0 0 4 65
Table 1. Distribution of FBLN2 expression in morphologically normal and cancerous breast. FBLN2 staining 
intensity in morphologically normal margins, areas of DCIS and in invasive areas of 65 breast cancer patients’ 
tissue sections (0 = negative; 1 = weak; 2 = intermediate; 3 = strong). NA: No available data.
www.nature.com/scientificreports/
7SCIeNtIfIC RepoRts |  (2018) 8:14139  | DOI:10.1038/s41598-018-32507-x
ducts, while loss of FBLN2 staining was evident in areas of invasion, where breakup of the normal ductal structure 
was evident by the loss of COLIV staining, with complete loss of both proteins in areas of invasion (Fig. 7).
High levels of Fbln2 mRNA are associated with better distant metastasis-free survival in lymph 
node negative and intermediate grade breast cancer patients. To further test our hypothesis of 
FBLN2′s positive contribution to controlling cancer growth and progression we assessed whether high Fbln2 
mRNA expression correlated with improved distant-metastasis-free survival (DMFS) in patients with breast can-
cer of different grades and LN status, using the Kaplan Meier plotter dataset27 (Supplementary Fig. 5). High levels 
of Fbln2 mRNA expression were indeed significantly associated with improved DMFS in patients with negative 
LN status (P = 0.03; n = 988), as well as in patients with intermediate grade (Grade II, P = 0.05; n = 546), while 
there was a statistically insignificant trend towards better survival in low grade breast cancer patients (Grade 
I, P = 0.14; n = 188). In contrast, in the high grade breast cancer patient group (Grade III (P = 0.023; n = 458)) 
higher Fbln2 mRNA levels were significantly associated with a poorer outcome, and showed a statistically insig-
nificant trend with poorer DMFS in patients with positive LN status (P = 0.14; n = 382). Although not fully 
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Figure 6. Immunohistochemical assessment of FBLN2 expression in relation to the collagen fibre network 
in normal ducts and lobules. (a–d) Immunohistochemical analysis of FBLN2 in normal ducts and lobules 
in regions of ducal carcinoma in situ (DCIS) and the boundary between a duct and the invasive area. (e–h) 
Picrosirus staining (red) showed a coherent fibrous collagen network in normal ducts and interlobular 
stroma where FBLN2 is expressed, but a much less coherent network in intralobular stroma, around DCIS 
and in invasive regions. (i–l) Alcian blue staining showed significant amount of GAGs (blue) in the stroma 
surrounding the tumour tissue where FBLN2 was absent and the collagen network was less intact. ‘N’ (normal), 
‘D’ (DCIS) and ‘I’ (invasive) describe the different areas within a section. Bars represent 200 μm.
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conclusive, this indicates that FBLN2 may play different roles at the early and advanced stage of breast cancer 
progression.
Discussion
We have previously shown that FBLN2 is upregulated in terminal end buds compared to ductal epithelium at 
puberty, as well as in myoepithelial cells of early pregnancy ducts when the first morphological changes become 
microscopically visible10, suggesting a role in the formation of the new BM during ductal (branching) morpho-
genesis. However, fbln2 knockout mice did not show any morphological defects likely due to compensation effects 
by other fibulins including FBLN110. Therefore, despite FBLN2’s highly distinct expression and localisation in 
the mouse mammary gland, FBLN2′s role in mammary tissue morphogenesis and homoeostasis has not been 
established. In this study, we investigated the effect of Fbln2 KD in mouse mammary epithelial cells and further 
studied its expression in human breast cancer.
EpH4 cells were the only normal mouse mammary cell line in our laboratory that expressed detectable levels 
of FBLN2 on mRNA and protein level (data not shown). We therefore used this cell line to produce stable knock-
down cells to study FBLN2′s possible role in the mammary gland. Reduced expression of FBLN2 in EpH4 cells 
grown in Matrigel produced larger spheroids than cells transfected with scrambled control shRNA. Although 
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Figure 7. Loss of FBLN2 and COLIV expression are associated with BM break up. Immunohistochemical 
analysis of FBLN2 and COLIV in breast cancer regions (DCIS) and morphologically normal tissue at three 
representative regions. ‘N’ (normal), ‘D’ (DCIS) and ‘I’ (invasive) describe the different areas within a section. 
Bars represent 100 μm and 200 μm.
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this could be attributed to a higher growth rate, no difference between control and KD EpH4 cells was identified, 
when the proliferation rate of each line was assessed (data not shown). In 2D culture, cells were larger and had 
enlarged nuclei although this was not observed when analysed by flow cytometry, indicating a larger cell spread. 
The change in morphology might be due to altered adherence to the plastic upon Fbln2 KD, possibly via changes 
in keratin expression and the cell cytoskeleton28,29.
On Matrigel, the increase in size of spheroids was associated with disruption of the surrounding COLIV 
sheath. This was accompanied by a significant reduction in integrin β1 expression. This increase in size was an 
unexpected result as block of integrin β1 binding to the ECM has previously been shown to result in suppressed 
growth30. However, the disruption of the BM after reduction in ITGβ1 is consistent with previous reports of 
mice lacking ITGα3/β1, which showed that reduced FBLN2 expression was associated with loss of epidermal 
BM integrity19. In contrast though, integrin α3 was still expressed in our KD cells when grown in an organotypic 
model and appeared up-regulated in cells grown on plastic. Whether other β-type integrins were upregulated to 
compensate for reduced levels of integrin β1 is unknown.
Although a direct interaction between fibulins and COLIV in BM has not been established, there is evidence 
for an indirect interaction. COLIV interacts with and binds to other BM components such as nidogen, perlican 
and laminin11,31, all of which are known binding partners of FBLN2. E.g. Nidogen is required for the link between 
COLIV and laminin for proper epithelial branching upon BM assembly32. Our results are consistent with this 
link being important for BM integrity, and that its loss can have a drastic effect on the growth of epithelial cells.
Moreover, cells interact with the BM through integrins33,34. As ITGβ1/α3 is a receptor for laminin, collagen 
and FN35,36, down regulation of ITGβ1 in Fbln2 KD cells could potentially affect the integrity of COLIV around 
epithelial cells disrupting the BM and impairing the interaction between epithelial cells and the surrounding 
BM/ECM. However, it may also be possible that loss of FBLN2 directly reduces ITGβ1 expression, which in turn 
leads to a change in COLIV network integrity. Such an impairment of BM integrity upon loss of ITGβ1 has pre-
viously been shown in models of lung and kidney morphogenesis37 and in epidermal development38, while loss 
of basolateral staining of ITGα2/β1 has been linked to the absence of COLIV expression in breast carcinoma39. 
Also consistent with the hypothesis that FBLN2 provides integrity of the BM, thereby enabling the BM to restrain 
uncontrolled epithelial outgrowth, is the excessive branching phenotype induced by fibroblasts as seen in our in 
vitro model. However, this branch pattern did neither resemble the controlled in vitro branch pattern of EpH4 
cells seen in response to growth factors40 nor of mammary organoids18, where epithelial branching emerges as 
multicellular buds.
A continuous mammary BM containing COLIV, laminins 111, 332, 511, and 5215,14,41 is associated with nor-
mal mammary ducts and stable stroma42. The results from our study are consistent with those findings, as FBLN2 
expression was mainly found around normal mammary ducts and in the interlobular stroma surrounded by a 
coherent fibrous collagen network (Fig. 6). FBLN2 was neither expressed in the intralobular stroma of normal 
tissue nor in invasive tissues, with both of them showing a loose fibrous collagen network. Interestingly, at the 
boundary between morphologically normal mammary duct, ductal carcinoma in situ, and invasive area, FLBN2 
was expressed in the region of normal duct but not at the invasive cancerous region where BM was absent. This is 
consistent with data from a Matrigel-embedded system, in which FBLN2 was able to reduce the invasion of breast 
cancer cell lines (MDA-MB-231 and BT-20)17.
The FBLN2 expression pattern in the normal adult human breast around tumour tissue differs strongly from 
that in the adult mouse where FBLN2 was only detected at times of BM remodelling during very early pregnancy. 
We have not evaluated human pubertal tissue to assess whether FBLN2 expression is found more strongly in 
areas of epithelial growth with new BM formation as was seen in the mouse. The reason for this difference in adult 
tissue expression is not clear, though it may either indicate an anatomical or structural difference in that FBLN2 
when incorporated into the ductal matrix of the human breast tissue is still accessible and therefore detectable, 
while inaccessible and therefore not readily detectable around mouse mammary ducts, or that FBLN2 in the 
human breast is not only present during the new formation and remodelling of the ducts, but may have functions 
during duct maintenance in the breast.
Studies have suggested FBLN2 contributes to metastasis and invasion in lung adenocarcinoma22, in pancre-
atic cancer cell lines43 and in transformed keratinocytes44. However, loss of FBLN2 protein expression has been 
reported in breast carcinoma17,45, and FBLN2 methylation has been demonstrated in five breast cancer cell lines46. 
The absence of FBLN2 in cancerous regions is consistent with our hypothesis that FBLN2 negatively controls 
invasive growth by interacting with and stabilizing the BM in areas of normal ductal stroma. This was further sup-
ported by the lack of FBLN2 expression in the stromal regions of tumours where the metastatic stromal markers 
TN-C, POSTN, and GAGs26,47,48 were all expressed, as well as FBLN2′s presence around normal ducts where these 
metastatic markers were absent. Such an invasive growth controlling role of FBLN2 would further be explained 
by the improved DMFS rate for breast cancer patients with LN negative or intermediate to low grade breast 
cancer, where the level of progression from DCIS to invasive growth could be the distinguishing factor. In con-
trast, when high grade patient groups were assessed, increased risk of distant metastatic spread in patients was 
indeed associated with higher expression levels of Fbln2 mRNA, with a similar trend for LN positive patients. 
This could indicate that in these groups, in which initial invasion through the BM has already occurred, FBLN2 
expression in the tumour cells could be advantageous for their growth during the later stages of progression, or 
potentially at the final step of micrometastasis formation when the tumour cells home into the tissue of the distant 
organ to form another malignant tumour. A similar mechanism has been suggested in lung adenocarcinoma, 
where FBLN2 might be required for the formation of the new ECM around tumour cells possibly originated 
from tumour-associated fibroblasts22. Furthermore, a potential dual role of Fbln2 has been reviewed previously49, 
showing that while Fbln2 was one of 64 up-regulated RNAs included in a solid tumour-derived metastasis signa-
ture50, other studies have also described it as a tumour suppressor in several different cancers, a general pattern 
typical of fibulins49. Whether this is due to its role as a BM stabilising protein or due to other factors regulated 
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by FBLN2 is unknown. One such potential candidate is TGFβ, which has been shown to have tumour suppres-
sive activity in early stages of cancer development, while enhancing invasion and metastasis formation in more 
advanced cancers51,52. FBLN2 enhances TGFβ activity53,54 and can also compete with latent TGFβ-binding protein 
for binding to fibrillin-155, thereby regulating TGFβ deposition within the ECM and bioavailability. However, 
unpublished data from our laboratory have also shown that TGFβ itself can activate FBLN2 expression in EpH4 
cells and primary mouse fibroblasts, so that it may be difficult to distinguish between cause and effect. In future 
studies, it could therefore be important to examine Fbln2′s role in the survival of tumour cells under conditions 
experienced during metastasis, as well as FBLN2 expression in both the metastasis itself and in the matched pri-
mary tumour.
Materials and Methods
Cell Culture. EpH4 cells expressing FBLN2 were passaged in 75 cm2 tissue culture filter flasks at 37 °C in a 
humidified atmosphere with 5% CO2. Cells were grown in DMEM (Thermo Fisher Inc., Surrey, UK)/10% FBS 
media (Thermo Fisher) supplied with 2 mM L-glutamine (Thermo Fisher), 100 U/ml penicillin (Thermo Fisher) 
and 100 µg/ml streptomycin (Thermo Fisher). Mammary fibroblasts were isolated as described previously56. 
Briefly: mammary glands were cut into very small pieces using sterile scalpels and incubated with collagenase A 
solution (Sigma Aldrich Company Ltd., Dorset, UK) at 2.5 mg/ml and 0.2% trypsin (Thermo Fisher) at 37 °C for 
30 min with mild agitation (130 rpm). The tissue homogenate was spun down at 1500 rpm for 10 min, the pellet 
was resuspended in DMEM/F12 medium, treated with DNase I (Sigma) at 2 U/ml for 10 min, and the DNase was 
removed by spinning the cells down at 1500 rpm for 10 min. Differential centrifugation was performed 5 times 
to separate epithelial cells from the stromal compartment. Finally, the stromal compartment was re-suspended 
in DMEM/F12 medium (Thermo Fisher) with 10% serum, and incubated at 37 °C in a humidified atmosphere 
with 5% CO2.
Production of lentivirus and transduction of EpH4 cells. For virus production, HEK-293 cells (70–
80% confluency) were transfected using X-tremeGENE 9 (Roche Diagnostics Ltd., Burgess Hill, UK) according 
to manufacturer’s manual with 3 μg pCMV-dR 8.91 (packaging vector, Thermo Fisher) + 0.7 μg pCMV-VSV-G 
(envelope vector, Thermo Fisher) + 3 μg Lentiviral shRNA vectors (three pLKO1-Puro vectors targeting all Fbln2 
variants of the mouse under control of the human U6 promotor (Clones: TRCN0000109479, TRCN0000109478 
and TRCN0000109476 (Thermo Fisher), or a scr ctrl shRNA pLKO1-Puro control vector (Thermo Fisher)). 
These were mixed in 100 µl of Opti-MEM (Thermo Fisher), 6 μl X-tremeGENE 9 was added, and the transfection 
solution applied to the cells. After overnight incubation, the medium was replaced with fresh DMEM/10%FBS 
medium, and incubated for another 24 hrs, after which the virus-containing medium was collected and filtered 
using syringe-driven filters (Millipore Ltd., Livingstone, UK). Filtered virus was added to EpH4 cells in a 6-well 
plate, incubated for 4 hrs at 37 °C in a 5% CO2 incubator, topped up with DMEM/10% FBS medium + 8 ug/ml 
polybrene (Sigma) and finally incubated for 24 hrs.
The medium was replaced with fresh medium containing 3 µg/ml puromycin (Sigma) for selection of trans-
duced cells. Cells were routinely passaged with puromycin-medium to maintain the selection.
Matrigel-embedding and epithelial growth in 3D system. Growth factor-reduced Matrigel™ matrix 
(Becton Dickinson (BD) UK Ltd., Oxford, UK) was thawed on ice overnight. 100 μl of Matrigel was added to each 
well of an eight-well chamber slide (Nunc, Sigma) to cover the surface of each chamber, and incubated at 37 °C 
for 30 min to solidify. 10,000 transduced EpH4 cells per chamber were re-suspended in DMEM-F12/serum free 
medium mixed with 5% Matrigel and plated on the Matrigel layer in each chamber. Cells were grown in serum 
free DMEM-F12 medium overnight after which the medium was replaced every other day with DMEM-F12/5% 
FBS for 7–8 days before microscopic analysis. For co-culture, fibroblasts and EpH4 cells were mixed in a 1:1 ratio 
and plated as above. For experimental end point quantification, the number of structures on low magnification 
was counted in two representative images for each condition; the mean number from biological replicates was 
then calculated.
Flow cytometry. Fbln2 KD and scr cells were trypsinised, washed with DPBS and re-suspended in DPBS at 
1 × 106 cells/ml. 100,000 cells were counted per experiment. Scr cells were used as the reference to assign cell size 
(Forward scatter, FSC) and granularity (side scatter, SSC) parameters. With the exclusion of dead cells, debris and 
clumped cells, each line was analysed for these parameters using BD FACSARIA II (BD) provided with FACSDiva 
Version 6.1.3 software.
Immunocytochemistry. Cells were fixed in 4% PFA (Sigma) for 20 min at RT followed by 1 min incubation 
in ice-cold methanol (Sigma). Cells were washed three times with PBS (Thermo Fisher), permeabilised with 
PBS + 0.5% Triton-100 (Sigma) for 10 min at 4 °C, and then rinsed with 100 mM glycine (Sigma) in PBS three 
times for 10 min each to reduce auto-fluorescence.
Cells were blocked with blocking buffer (PBS+ 10% FBS, 7.7 mM NaN3 (Sigma), 0.1% BSA (Thermo Fisher), 
0.2%Triton (Sigma) x-100, 0.05% Tween-20 (Sigma)) with rocking for 1 hr at RT and then incubated with the 
primary antibody (FBLN2 at 1:10,000 (kind gift from M-L. Chu7), ITGβ1 (BD, 550531) at 1:100, ITGα3 (kind gift 
from C.M. DiPersio19) at 1:400 and COLIV (Abcam, Cambridge Science Park, Cambridge, UK, ab6586) at 1:500) 
diluted in blocking buffer.
Cells were washed three times with blocking buffer on a rocking platform, and incubated with the appropriate 
Alexafluor 488- or 594-conjugated secondary antibody (Thermo Fisher) diluted in blocking buffer in the dark 
for 1 hr at RT. Cells were washed with PBS three times with rocking and finally mounted using Prolong Gold 
containing DAPI (Thermo Fisher) to counterstain nuclei. 3D spheroids were visualised with a LSM 780 confocal 
microscope (Carl Zeiss Ltd., Cambridge, UK) using a Z-stacking module, and 2D stained cells were visualised 
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with an Olympus IX51 inverted fluorescence microscope (Olympus Ltd., Surrey, UK) using CellP Imaging soft-
ware (Olympus).
RNA Isolation and Quantitative RT-PCR. RNA was extracted using Direct-zol™ RNA MiniPrep (Zymo 
Research Corporation, Irvine, USA) as per manufacturer’s instructions. The RNA was reconstituted in RNase-free 
water and quantified using the Nanodrop ND-1000 Spectrophotometer (Thermo Fisher). cDNA was produced 
using 200–500 ng RNA with Superscript II (Thermo Fisher) and random primers according to manufacturer’s 
instructions. PCR reactions were carried out using a LightCycler® 480 Instrument (Roche) with the appropriate 
Lightcycler probes under standard conditions. Each reaction mixture contained 1 μl (0.25 μM) of probe, 1 μl of 
primer mixture (7.2 μM of both forward and reverse primers), 10 μl of 2x LightCycler® 480 TaqMan Master Mix 
(Roche), 5 μl of diluted cDNA and dH2O to a final reaction volume of 20 μl. The following primers (Sigma) were 
used: FBLN2: Fwd 5′- tgttgttggggacacagcta −3′, Rev 5′- ccatcaaacactcgtcttggt −3′, Probe (#22), Beta actin: Fwd 
5′- aaggccaaccgtgaaaagat −3′, Rev 5′- gtggtacgaccagaggcatac −3′, probe (#56). Relative RNA expression was cal-
culated by the 2−ΔΔCt method.
Protein isolation and western blotting. Cells were collected and lysed in ice-cold RIPA buffer (25 mM 
TRIS (Sigma) pH 8, 150 mM NaCl (Sigma), 1% NP-40 (Sigma), 1% sodium deoxycholate (Sigma), 0.1% SDS 
(Sigma), with protease inhibitor cocktail (Roche) and phosphatase inhibitors (sigma) in dH2O. The suspension 
was pipetted up and down through a 1 ml syringe to break up cells and chromatin, and kept on ice for 5 min. The 
cell lysate was centrifuged at 4 °C for 20 min at 21,000 g and the soluble protein in the supernatant was quantified 
using a Pierce™ BCA Protein Assay Kit as per manufacturer’s instructions (Thermo Fisher). 50 μg of denatured (in 
1xLDS-loading buffer with 0.1 M DTT) protein per sample was separated on a Novex NuPage™ Electrophoresis 
(Thermo Fisher) system using 4–12% Bis-Tris-HCl buffered gels in the presence of 1xNuPage MES SDS running 
buffer (Thermo Fisher). Proteins were transferred onto Whatman® Protran® Nitrocellulose Transfer Membrane 
(0.2 μm) (GE Healthcare Bio-Sciences, Pitsburgh, PA, USA) using a Novex XCell II™ Blot module (Thermo 
Fisher). Successful transfer was confirmed by PonceauS (Sigma) staining. The blot was then incubated for 40 min 
at RT in blocking solution (3–5% dried skimmed milk powder in wash buffer (1X PBS/0.1% Tween-20)), fol-
lowed by incubation for 2 hrs at RT with the appropriate primary antibody (goat anti-actin at 1:200 (Santa Cruz 
Biotechnology INC., Santa Cruz, USA, Sc-1615), rabbit anti-FBLN2 at 1:10,000, rabbit anti-ITGβ1 at 1:500 and 
rabbit anti-ITGα3 at 1:1000. After three 10 min washes with wash buffer, the blot was incubated for 1 hr at RT 
with horseradish peroxidase (HRP)-labelled secondary antibody (Thermo Fisher) in blocking buffer, and finally 
washed three times with wash buffer for 10 min.
A chemi-luminescence reaction was carried out using the ECL Western blotting detection reagent kit (Thermo 
Fisher) as per manufacturer’s instructions. The signal was detected using an Intelligent Dark Box LAS-3000 
(Fujifilm UK Ltd., Sheffield, UK) equipped with a cooled CCD camera. Images were acquired and analysed using 
LAS-3000 v.2.2 software (Fujifilm).
Filters were cut into the appropriate size ranges (at ~60 kDa) to allow for multiple antibody incubation of 
the same samples (FBLN2/actin; ITGβ1/actin). Where this was not possible, filters were stripped under mild 
conditions (15 min in 0.1% SDS/0.1% Tween-20 (pH2)) and complete removal of antibodies was tested before 
re-incubation with another primary antibody (FBLN2/ITGα3).
Human patient data. 65 breast cancer patients were recruited from breast clinics at Cairo University, Kasr 
Alainy Hospital upon signed informed consent from all participants and with the acceptance of Cairo University 
ethical committee (IRB: N-8–2017). All research was performed in accordance with relevant guidelines and 
regulations. Patients’ ages ranged from 32 to 72 years old, with mean age 53 ± 12. Clinical and pathological fea-
tures of patients’ cohort including tumour grade, lymph node (LN) involvement, lymph-vascular invasion were 
established and the expression of hormone and growth factor receptors (ER, PR and HER-2) all assessed by IHC 
(Supplementary Table 1).
Pathological grade of tumour and margins of surgical excision were estimated using haematoxylin & eosin 
archival stained sections. Normal breast ducts were identified by an intact basement membrane, double epithe-
lial and myoepithelial cell lining with regular nuclei and fine chromatin. Areas of DCIS were defined by regular 
rounded contours, intact basement membrane with peripheral myoepithelial layer, and filled with multiple layers 
of malignant epithelial cells having large nuclei coarse chromatin and occasional nucleoli. Invasive carcinoma 
was defined as having formed small or large groups of malignant epithelial cells, with some forming tubules with 
irregular contours, with neither myoepithelial layer nor basement membrane present.
Fibrous collagen and GAG staining. 5 μm sections routinely cut from formalin fixed, paraffin 
wax-embedded (FFPE) tissue sections were deparaffinised in xylene (Sigma) for 10 min, re-hydrated in decreas-
ing concentrations of ethanol (Sigma) and finally soaked in tap water. For collagen I and III staining, slides were 
incubated in Picrosirus red stain (Abcam) for 1 hr and then washed in 0.5% acetic acid (Sigma) for stain differ-
entiation. For GAG staining, slides were incubated in Alcian blue stain (Sigma) for 20 min57 and counterstained 
with eosin (Dako UK Ltd., Eli, UK). Slides were then dehydrated in increasing concentrations of ethanol, cleared 
in two changes of xylene and finally mounted with DPX mounting medium (Sigma).
Immunohistochemistry of human breast sections. Antigen retrieval was performed on 5 μm FFPE 
human breast tissue sections using 1 mM EDTA (Sigma) buffer (pH 8) under high pressure and all other incu-
bations were performed at RT using a humidified chamber. Sections were blocked with pre-diluted 2.5% goat 
serum (Thermo) for 20 min and incubated with primary antibody for 30 min. All antibodies were diluted to 
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their final concentrations using Antibody Diluent (Dako) (FBLN2 1:10,000; COLIV 1:400 (Abcam, ab6586); 
TN-C 1:200 (Abcam, ab108930); POSTN 1:150 (Santa Cruz, Sc-49480); Vimentin (Vim) 1:100 (Abcam, ab8978); 
Smooth muscle actin (SMA) 1:200 (Thermo Fisher, MS-113P). Sections were washed thrice and then incubated 
for 30 min with HRP-conjugated goat polyclonal anti-rabbit/anti-mouse (Dako) for FBLN2, COLIV, SMA, Vim 
and TN-C, and horse anti-goat for POSTN (HRP labelled) secondary antibody diluted 1:500 (Vector Laboratories 
Ltd.; Peterborough, UK), prior to staining with DAB + Chromogen (Dako) for 4 min. Stained tissue sections were 
counterstained with haematoxylin (Dako), dehydrated through increasing concentrations of ethanol and xylene 
before mounting with cover slips using DPX mounting medium (Sigma). Negative controls (lacking primary anti-
body) were used in each staining run. All 65 breast tumours were assessed for FBLN2 expression, while COLIV, 
POSTN, SMA, Vim and TN-C were each assessed in 10 randomly chosen consecutive sections. Scoring of FBLN2 
expression was performed based on visual assessment of staining intensity and the number of stained structures, 
and was given values from 0 (negative) to 3 (strong).
Statistical analysis. FBLN2 expression in normal, DCIS and invasive regions in the 65 patients’ sections 
was analysed for associations with hormone receptors (ER, PR) and growth factor receptor (HER2) expression 
as well as histological grade. A Pearson’s test was used to assess the association between the score number of each 
region and the other parameters. All tests were two sided. P-values < 0.01 were considered statistically significant.
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